CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3

Inflammation

Volumn 38, Issue 6, 2015, Pages 2049-2056

  Tang, Qiu ^a   Jiang, Jun ^a   Liu, Jian ^b  

^a CENTRAL HOSPITAL OF WUHAN   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

CCR5; IL 6; melanoma; SOCS3; Stat3

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GELATINASE B; INTERLEUKIN 6; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; ANTINEOPLASTIC AGENT; CCR5 PROTEIN, MOUSE; CD3 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; GR-1 PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE; MMP9 PROTEIN, MOUSE; MONOCLONAL ANTIBODY; SOCS3 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER TISSUE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; MELANOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR VOLUME; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; INTERLEUKIN-6; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MATRIX METALLOPROTEINASE 9; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; PHOSPHORYLATION; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84946488091     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-015-0186-1     Document Type: Article

References (27)

1. Stewart, T.J., and M.J. Smyth. 2009. Chemokine—chemokine receptors in cancer immunotherapy. Immunotherapy 1: 109–127.
2. Murphy, P.M., M. Baggiolini, I.F. Charo, C.A. Hebert, R. Horuk, K. Matsushima, L.H. Miller, J.J. Oppenheim, and C.A. Power. 2000. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews 52: 145–176.
3. Luster, A.D. 1998. Chemokines—chemotactic cytokines that mediate inflammation. New England Journal of Medicine 338: 436–445.
4. Schlecker, E., A. Stojanovic, C. Eisen, C. Quack, C.S. Falk, V. Umansky, and A. Cerwenka. 2012. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. Journal of Immunology 189: 5602–5611.
5. Bedognetti, D., T.L. Spivey, Y. Zhao, L. Uccellini, S. Tomei, M.E. Dudley, M.L. Ascierto, V. De Giorgi, Q. Liu, L.G. Delogu, et al. 2013. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British Journal of Cancer 109: 2412–2423.
6. Song, J.K., M.H. Park, D.Y. Choi, H.S. Yoo, S.B. Han, D.Y. Yoon, and J.T. Hong. 2012. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS One 7, e33747.
7. Kim, H.K., H. Zhang, H. Li, T.T. Wu, S. Swisher, D. He, L. Wu, J. Xu, C.A. Elmets, M. Athar, X.C. Xu, and H. Xu. 2008. Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma. Neoplasia 10: 1411–1420.
8. Katz, A., L.M. Shulman, M. Revel, M. Feldman, and L. Eisenbach. 1993. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas. International Journal of Cancer Journal International du Cancer 53: 812–818.
9. Horiguchi, A., T. Asano, K. Kuroda, A. Sato, J. Asakuma, K. Ito, et al. 2010. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. British Journal of Cancer 102: 1592–1599.
10. Gabrilovich, D.I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 9: 162–174.
11. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews 222: 162–179.
12. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by L-arginine metabolism. Nature Reviews Immunology 5: 641–654.
13. Karin, M., Y. Cao, F.R. Greten, and Z.W. Li. 2002. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2: 301–310.
14. Lee, N.J., D.Y. Choi, J.K. Song, Y.Y. Jung, D.H. Kim, T.M. Kim, D.J. Kim, S.M. Kwon, K.B. Kim, K.E. Choi, et al. 2012. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model. Carcinogenesis 33: 2520–2528.
15. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology 7: 41–51.
16. Hirano, T., K. Ishihara, and M. Hibi. 2000. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19: 2548–2556.
17. Wormald, S., and D.J. Hilton. 2004. Inhibitors of cytokine signal transduction. Journal of Biological Chemistry 279: 821–824.
18. Pandey, M.K., B. Sung, and B.B. Aggarwal. 2010. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. International Journal of Cancer 127: 282–292.
19. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 182: 4499–4506.
20. Chandra, D., and C. Gravekamp. 2013. Myeloid-derived suppressor cells: cellular missiles to target tumors. Oncoimmunology 2, e26967.
21. Liu, C., S. Yu, J. Kappes, J. Wang, W.E. Grizzle, K.R. Zinn, and H.G. Zhang. 2007. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109: 4336–4342.
22. Darnell Jr., J.E. 1997. STATs and gene regulation. Science 277: 1630–1635.
23. Jarnicki, A., T. Putoczki, and M. Ernst. 2010. Stat3: linking inflammation to epithelial cancer—more than a “gut” feeling? Cell Division 5: 14.
24. Aoki, Y., G.M. Feldman, and G. Tosato. 2003. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535–1542.
25. Yu, H., and R. Jove. 2004. The STATs of cancer—new molecular targets come of age. Nature Reviews Cancer 4: 97–105.
26. Endo, T.A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921–924.
27. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nature Reviews Immunology 7: 454–465.